Ergomed PLC (LON:ERGO)‘s stock had its “buy” rating reaffirmed by stock analysts at Numis Securities Ltd in a research report issued to clients and investors on Friday. They presently have a GBX 280 ($3.71) price objective on the stock. Numis Securities Ltd’s price objective suggests a potential upside of 54.27% from the stock’s previous close.

Ergomed PLC (ERGO) opened at 181.50 on Friday. Ergomed PLC has a 52 week low of GBX 118.00 and a 52 week high of GBX 216.88. The company’s market capitalization is GBX 73.57 million. The firm has a 50-day moving average price of GBX 177.40 and a 200-day moving average price of GBX 191.79.

Ergomed PLC (LON:ERGO) last issued its earnings results on Monday, September 18th. The company reported GBX 1.20 ($0.02) earnings per share (EPS) for the quarter. Ergomed PLC had a return on equity of 2.69% and a net margin of 2.07%. The firm had revenue of GBX 2,291 million for the quarter. Analysts anticipate that Ergomed PLC will post $7.80 EPS for the current fiscal year.

WARNING: “Ergomed PLC (ERGO) Stock Rating Reaffirmed by Numis Securities Ltd” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at

Ergomed PLC Company Profile

Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services.

Receive News & Stock Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related stocks with our FREE daily email newsletter.